What’s Next for Enanta Pharmaceuticals Inc (ENTA) After Today’s Huge Increase?

September 17, 2017 - By Peter Erickson

Investors sentiment decreased to 1.47 in Q4 2016. Its down 0.06, from 1.53 in 2016Q3. It dived, as 13 investors sold Enanta Pharmaceuticals Inc shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported.
Moreover, Nationwide Fund Advsrs has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 11,925 shares. Metropolitan Life Insur Ny accumulated 11,660 shares or 0% of the stock. Spark Lc reported 190,800 shares stake. Numeric Investors Ltd Liability holds 100,000 shares. Envestnet Asset Mgmt owns 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 8,783 shares. State Teachers Retirement System accumulated 0% or 38,190 shares. State Of Alaska Department Of Revenue has invested 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Federated Investors Pa reported 460 shares stake. Credit Suisse Ag invested in 0% or 34,942 shares. Acadian Asset Mgmt Limited Liability Corp reported 568,686 shares. Da Davidson invested in 0% or 1,735 shares. Prelude Capital Mngmt Ltd Liability Company reported 6,002 shares. American Intl invested in 11,170 shares or 0% of the stock. Great Point Ptnrs Ltd Co owns 5.7% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 828,253 shares. Hanson Mcclain holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 100 shares.

The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! The stock increased 4.55% or $1.96 on September 15, reaching $45.06. About 355,589 shares traded or 88.35% up from the average. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since September 17, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.
The move comes after 8 months positive chart setup for the $860.21 million company. It was reported on Sep, 17 by Barchart.com. We have $48.66 PT which if reached, will make NASDAQ:ENTA worth $68.82 million more.

Investors wait Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report on November, 20. its quarterly earnings Wall Street analysts expect $1.94 EPS, up $2.03 or 2,255.56 % from last year’s $-0.09 same quarter earnings. This translates into $37.04 million profit for ENTA giving the stock a 5.81 P/E. This is assuming the current $1.94 EPS is accurate. Enanta Pharmaceuticals Inc’s Wall Street analysts see -540.91 % EPS growth, taking into account the $-0.44 EPS reproted in the previous quarter,

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Enanta Pharmaceuticals Inc had 14 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Market Outperform” rating on Tuesday, July 11 by JMP Securities. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) earned “Mkt Outperform” rating by JMP Securities on Friday, October 23. The rating was downgraded by Zacks to “Buy” on Friday, August 7. The firm has “Underweight” rating by Barclays Capital given on Friday, October 23. On Tuesday, August 9 the stock rating was maintained by JP Morgan with “Overweight”. The firm has “Market Perform” rating by JMP Securities given on Thursday, April 28. The rating was maintained by Robert W. Baird with “Neutral” on Tuesday, August 8. On Saturday, August 8 the stock rating was downgraded by TheStreet to “Buy”.

More notable recent Enanta Pharmaceuticals Inc (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Q2 2017 Results – Earnings Call …” on May 08, 2017, also Seekingalpha.com with their article: “Biotech Forum Daily Digest: Fallout From The ACA Repeal Debacle. Spotlight On …” published on March 27, 2017, Seekingalpha.com published: “Enanta: Half Cash, All Upside” on February 28, 2017. More interesting news about Enanta Pharmaceuticals Inc (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Enanta Pharmaceuticals: Updates To Thesis” published on August 06, 2017 as well as Seekingalpha.com‘s news article titled: “Enanta To Retain Momentum On The Back Of Upcoming FDA Decision” with publication date: July 10, 2017.

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The company has market cap of $860.21 million. The Firm uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. It currently has negative earnings. The Company’s research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: